Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.11 0.33 −9.59%
Market cap
$13.0M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Where the cash went Fiscal 2025, year to 31 December 2025

Free cash flow was −$4.8M: capital expenditures were more than operating cash flow. Cash fell by $54.3M. Lines the picture does not name came to −$4.4M. What is a cash flow statement?

Free cash flow
−$4.8M
Returned to shareholders
$0.00
Debt, net
−$80.6M repaid
Change in cash
−$54.3M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Capital expenditures0.0
Free cash flow0.0
Acquisitions, net+0.1
Into investments, net−0.1
Debt repaid, net−0.1
Other0.0
Change in cash−0.1
Operating cash flow, capex and free cash flow, ten yearsOperating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Operating cash flow$0.0B−$0.1B−$0.1B−$0.1B$0.1B−$0.1B−$0.1B−$0.3B−$0.1B$0.0B
Capex$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Free cash flow$0.0B−$0.1B−$0.1B−$0.1B$0.1B−$0.1B−$0.1B−$0.3B−$0.1B$0.0B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Net Income
(58.07) (120.87) (86.42) (76.97) (189.29) (290.02) (293.65) (284.23) (47.58) 183.45
Depreciation & Amortization
8.77 7.94 6.52 17.79 22.15 17.29 12.22 4.87 1.01 0.68
Non Cash Items (Other)
31.88 37.40 52.15 66.14 74.11 130.42 65.07 84.03 26.03 (35.87)
Accounts Receivable Change
4.96 2.00 (55.23) 35.23 (11.97) 25.18 0.77 3.43 (6.74) (2.54)
Change in inventories
— — — (6.89) (9.17) (14.16) (11.00) (1.69) 22.28 5.36
Accounts Payable Change
(0.30) (0.71) 3.63 (3.05) 17.73 0.81 5.91 (15.51) 14.51 (27.65)
Change in payables and accrued liability
2.97 9.20 5.61 17.71 30.91 16.38 90.56 (49.78) (91.53) (45.51)
Change in other assets and liabilities
16.90 (1.46) (2.40) (128.66) 147.13 31.88 (15.80) (56.13) (55.98) (82.69)
Operating Cash Flow
7.11 (66.51) (76.14) (78.70) 81.60 (82.23) (145.93) (315.02) (138.00) (4.77)
Capital expenditures
(1.25) (8.49) (7.84) (5.75) (3.99) (5.19) (3.73) (2.52) 0.78 (0.04)
Change in intangibles (net)
— — — — 0.00 (25.00) (35.00) — — —
Net Aquisitions
— — — — — — — — — 96.62
Short Term Investments Change (Net)
7.87 (0.17) (576.88) (411.30) 2.41 (479.93) (156.64) (245.10) (8.63) (61.16)
Long-Term Investments Change (Net)
— 78.53 62.59 537.07 454.07 83.14 284.49 400.62 133.84 —
Other investing activities
(2.74) (9.24) (15.61) (12.75) (11.46) (32.37) 8.13 0.66 — —
Investing cash flow
6.62 69.87 (522.12) 120.02 452.49 (426.97) 89.12 153.66 125.99 35.42
Repayment/Issuance of Debt (Net)
(0.40) (0.40) (0.36) (12.33) (13.02) (5.89) (0.54) 73.59 (0.04) (80.56)
Equity Repurchase (Common, Net)
9.88 506.12 29.85 20.78 37.83 12.70 4.18 52.14 0.14 —
Other financial activities
(2.74) (9.24) (15.61) (12.75) (11.46) (7.37) 43.13 (2.98) (0.35) (5.47)
Financing cash flow
6.74 496.47 13.88 (4.30) 13.34 (0.56) 46.78 122.75 (0.25) (86.03)
Exchange Rate Adjustment
(0.01) 0.05 (0.01) 0.00 4.70 2.60 (5.48) (3.40) 0.75 1.08
Change in Cash
20.46 499.88 (584.40) 37.01 552.13 (507.17) (15.52) (42.01) (11.51) (54.31)
Beginning Cash
153.32 173.78 673.66 89.26 126.27 678.39 171.22 155.70 113.69 102.18
Ending Cash
173.78 673.66 89.26 126.27 678.39 171.22 155.70 113.69 102.18 47.87
Stock Based Compensation
32.13 37.54 52.14 66.27 72.72 71.16 65.60 50.77 25.22 6.58
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
24.52 9.02 (48.40) (85.66) 174.63 60.08 70.43 (119.69) (117.46) (153.03)
Investments Change (Net)
7.87 78.36 (514.29) 125.77 456.48 (396.79) 127.85 155.52 125.21 (61.16)
Issuance/Purchase of Shares
9.88 506.12 29.85 20.78 37.83 12.70 4.18 52.14 0.14 —
Other line items
Revenue per Employee
0.50 0.31 0.46 0.48 0.29 0.42 0.24 0.10 0.13 0.19

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026